5.29
前日終値:
$5.04
開ける:
$5
24時間の取引高:
115.31K
Relative Volume:
0.09
時価総額:
$14.41M
収益:
-
当期純損益:
$-23.36M
株価収益率:
-7.1797
EPS:
-0.7368
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-27.03%
1か月 パフォーマンス:
-42.00%
6か月 パフォーマンス:
-70.61%
1年 パフォーマンス:
-74.81%
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
名前
Calidi Biotherapeutics Inc
セクター
電話
(858) 794-9600
住所
4475 Executive Drive, Suite 200, San Diego
CLDI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CLDI
Calidi Biotherapeutics Inc
|
5.29 | 14.41M | 0 | -23.36M | 0 | -0.7368 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-11-22 | 開始されました | H.C. Wainwright | Buy |
2023-10-09 | 開始されました | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc (CLDI) 最新ニュース
Calidi Biotherapeutics Reports Q2 2025 Financial Results and Advances in Oncology Therapies - citybuzz -
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - ADVFN Brasil
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pensacola News Journal
Calidi Biotherapeutics Q2 2025: Net Loss Narrowed to $5.7 Million, Cash Decreased to $5.3 Million. - AInvest
Calidi Biotherapeutics Secures FDA Fast Track Designation - TipRanks
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Bio Secures FDA Fast Track for Revolutionary Cancer Treatment as Q2 Shows Strong Pipeline Progress - Stock Titan
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split - TipRanks
Why LyondellBasell Industries Stock Slumped Today - The Globe and Mail
How does Calidi Biotherapeutics Inc. compare to its industry peersIdentify safe investments with exceptional yields - Jammu Links News
What is Calidi Biotherapeutics Inc. company’s growth strategyAchieve breakthrough gains with smart trades - Jammu Links News
Is it the right time to buy Calidi Biotherapeutics Inc. stockExtraordinary performance - Jammu Links News
1 Green Flag for Dutch Bros Stock Right Now - The Globe and Mail
Does Calidi Biotherapeutics Inc. stock perform well during market downturnsGet timely advice on market trends - Jammu Links News
Is Calidi Biotherapeutics Inc. a growth stock or a value stockAchieve consistent profits with smart trading - Jammu Links News
What are analysts’ price targets for Calidi Biotherapeutics Inc. in the next 12 monthsBuild a winning portfolio with smart picks - Jammu Links News
What makes Calidi Biotherapeutics Inc. stock price move sharplyDiscover high-impact stocks for growth - Jammu Links News
Is Calidi Biotherapeutics Inc. stock overvalued or undervaluedExceptional trading results - Jammu Links News
What are the technical indicators suggesting about Calidi Biotherapeutics Inc.Pre Market Entry Points To Watch Now - Jammu Links News
Chart based analysis of Calidi Biotherapeutics Inc. trendsChart Driven High Reward Trading Setup Presented - metal.it
Live Scanner Shows Breakout on Calidi Biotherapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Calidi Biotherapeutics Stock Plunges 10.6% Despite FDA Fast Track Designation - AInvest
Is it too late to sell Calidi Biotherapeutics Inc.AI Screener Based Stock Summary Report - Newser
What risks could impact Calidi Biotherapeutics Inc. stock performanceFree Stock Screener With Smart Filters - Newser
Candlestick signals on Calidi Biotherapeutics Inc. stock todayLong-Term Stock Growth Forecast Insights - Newser
Calidi Biotherapeutics Receives FDA Fast Track Designation - GlobeNewswire
Short Covering May Lift Calidi Biotherapeutics Inc. in Near TermShort Term High Yield Stock Tips for Active Traders - metal.it
Calidi Skyrockets 24.64% – Will the Biotech’s Volatility Fuel a Breakout or Backlash? - AInvest
Calidi Biotherapeutics Stock Soars 68% on FDA Fast Track Designation - AInvest
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma - The Manila Times
FDA grants fast track designation to Calidi’s CLD-201 for sarcoma - Investing.com
FDA Fast-Tracks Revolutionary Stem Cell-Viral Therapy for Aggressive Cancer Treatment - Stock Titan
Is Calidi Biotherapeutics Inc. a Top Dividend Stock to Watch in 2025Early Entry Ideas with Momentum Potential - Newser
Calidi Biotherapeutics Inc. Stock Support and Resistance Levels You Should KnowValue Investing Checklist with Entry Signals - Newser
Why Calidi Biotherapeutics Inc. stock attracts strong analyst attentionMarket Ready Picks with Technical Support - Newser
Published on: 2025-07-29 02:14:07 - Newser
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics - citybuzz -
How to forecast Calidi Biotherapeutics Inc. trends using time seriesPrice Action Summary and Entry Strategy Guide - Newser
How to interpret RSI for Calidi Biotherapeutics Inc. stockShort Term Opportunity Finder with Tools - Newser
Why Did Calidi Biotherapeutics Stock Plunge 10.55%? - AInvest
Calidi Biotherapeutics Inc (CLDI) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):